Clinical trial

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

NCT00821600

Study summary

ClinicalTrials.gov

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention risperidone IR and LAI formulation Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-12-01

PhasePHASE1

Conditions

Psychotic Disordersunresolved

Schizophreniaverified · MONDO: schizophrenia

Interventions

risperidone IR and LAI formulationDRUG

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Mapped research locations

AtlantaGeorgia, United States1 Santa AnaCalifornia, United States1 CerritosCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00821600 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.